AlloVir welcomes Shawn Tomasello to its Board of Directors

– USA, MA –  AlloVir (Nasdaq: ALVR), a late-clinical stage allogeneic T-cell immunotherapy company, today announced the appointment of Shawn Tomasello to its Board of Directors, bringing more than 35 years of broad experience building and leading commercial organizations in the life sciences industry, with specific expertise in cell and gene therapy.

“We’re thrilled to welcome Shawn to our Board of Directors. Her depth of experience in building successful biopharmaceutical companies and leading innovative cell and gene therapies from clinical development to commercialization is invaluable to AlloVir, as we advance our multi-virus-specific T cell platform and evolve into a commercial-stage company,” said CEO, Dr. Diana Brainard.

Concurrently, John Wilson will retire from the Board at the 2022 AGM.

About Shawn Tomasello

Shawn Tomasello has extensive strategic experience in building world-class organizations encompassing commercial, compliance, regulatory, pricing and medical affairs functions. From 2015 to 2018, Ms. Tomasello served as CCO of Kite Pharma, where she oversaw the global commercialization of the CAR T-cell therapy Yescarta® and played a key role in the company’s acquisition by Gilead Sciences. She previously served as CCO of Pharmacyclics, where she led both commercial and medical affairs. Prior to Pharmacyclics, Ms. Tomasello served as President of the Americas, Hematology and Oncology at Celgene, where she led the company through five successful product launches encompassing 11 indications and played a critical role in acquisitions. She currently serves on the boards of TCR2 Therapeutics, 4D Molecular Therapeutics, UroGen Pharma, Mesoblast, Gamida Cell and Centrexion Therapeutics.

Ms. Tomasello received a Bachelor of Science in Marketing from the University of Cincinnati and a Master of Business Administration from Murray State University in Kentucky.

About AlloVir

AlloVir is a leading late clinical-stage cell therapy company with a focus on restoring natural immunity against life-threatening viral diseases in pediatric and adult patients with weakened immune systems. The company’s innovative and proprietary technology platforms leverage off-the-shelf, allogeneic, single- and multi-virus-specific T cells for patients with T cell deficiencies who are at risk from the life-threatening consequences of viral diseases. AlloVir’s technology and manufacturing process enable the potential for the treatment and prevention of a spectrum of devastating viruses with each single allogeneic cell therapy. The company is advancing multiple mid- and late-stage clinical trials across its product portfolio.

For more information : https://www.allovir.com/

- DisclaimerNews, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.